The process of ageing and ageing-related disorders is associated with a variety of imbalance in homeostasis, eg, oxidative stress, genotoxic stress and an abundance of accumulating proteotoxic waste products. Many types of cellular damages including DNA damage, mitochondrial damage, telomere attrition and accumulation of macromolecular waste may promote ageing by driving cellular senescence, apoptosis, or dysfunction. The damage of cellular macromolecules and organelles is thought to be the triggering force behind ageing and ageing-related diseases.
of two different pathways, namely canonical and noncanonical.
The canonical pathway involves a variety of steps, including the phosphorylation, ubiquitination, and degradation of the IκBα, which enables the nuclear translocation of the p50-p65 subunits of NF-κB followed by p65 methylation, DNA binding, phosphorylation, acetylation, and gene transcription. I kappa B kinase (IKK) phosphorylates inhibitor of NF-kB, inducing its ubiquitination and proteasomal degradation, which then facilitates the nuclear translocation of NF-kB complexes predominantly p50/c-ReI and p50/ ReIA dimers. The p50/ReIA activation induces the transcription of several pro-inflammatory genes so plays a prominent role in inflammation. The noncanonical pathway, which leads to the activation of the p52/RelB dimer, includes different signalling molecules. [8] [9] [10] NF-kB triggers several of these cellular alterations and has been reported to be permanently activated in some types of cancer cells, and abnormalities in the NF-kB regulation are related to the pathogenesis of inflammatory diseases and cancer. With much controversy as to its role in tumour formation, the dual ability of p50 dimer to both repress and activate gene transcription prompts a complex relationship between this NF-kB subunit and cancer. A large and growing body of literature has highlighted the ageing-related constitutive activation of the NF-kB system and the role of oxidative stress in the sustained activation of the NF-kB system during ageing and inflammatory diseases. Interestingly, they have not detected any "ageing-related changes" in the expression levels of NF-kB or IkB component mRNAs. [4] [5] [6] [7] However, Forman et al 11 demonstrated the decrease of NF-kB p50, p52, p65 from cytosol to nuclei in the hearts from senescence-accelerated prone mice (SAMP8) together with a decreased of IkB. It is also crucial to note that the lungs of old SAMP8 mice showed a remarkable increase in their pro-inflammatory, pro-apoptotic and pro-oxidant status, in contrast with senescence-accelerated resistant mice. 12 Strikingly, many of the longevity factors are inhibitors of NF-kB signalling, either directly or indirectly.
An inhibitor of NF-kB, metformin is often used as an anti-diabetic medication in type 2 diabetes mellitus (T2DM), throughout the world and appears to be a potential anti-ageing agent. It has become a potential therapeutic candidate in the improvement of ageing and ageing-related diseases, including T2DM, cancer, obesity, and cardiovascular diseases ( Figure 1 ). The protective effects against diabetic complications have been observed with metformin monotherapy. 13 Metformin suppresses hyperglycaemia-induced reactive oxygen species (ROS) generation and oxidative stress in endothelial, and smooth muscle cells. 14, 15 We have previously demonstrated that metformin causes amelioration of antioxidant activities in various tissues and limits lipid peroxidation both in vivo and in vitro.
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| FREE R AD I C AL /OXIDATIVE S TRE SS THEORIE S OF AG EING
The free radical/oxidative theory is a well-known ageing theory.
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Free radicals can react with DNA, proteins, and lipids, and produce toxic constituents. 19, 20 The antioxidant systems are unable to counterbalance all the free radicals continuously generated during the life of the cell. This results in oxidative damage in the cell and thus in the tissues. 3, 21 Aged animals have shown a higher index of oxidation than young ones, and indeed various cellular compounds such as oxidized proteins, DNA forms, and lipids are accumulated. This damage can be attributed to an increased rate of free radical production in aged organisms. The elevated levels of ROS are involved in oxidative stress associated with the age. 22, 23 We previously reported that the intact erythrocytes of aged subjects are equally capable of withstanding the oxidative stress induced by cumene hydroperoxide, although there is a decrease in membrane defence with ageing. 24 Oxidative stress is undoubtedly one of the reasons for ageing due to the progressive increase of protein glycation. Protein glycation products are called advanced glycation end products (AGE) F I G U R E 1 Metformin shows its potential effects of the action on a variety of diseases and oxidative stress and hyperglycaemia can modify the formation of these AGE products. 13 It seems that AGE, with the induction which ultimately leads to cellular failure. MFRTA should not be easily discarded since there is an agreement in that ROS is not simply a critical toxic metabolic by-product, but also an irreplaceable signalling switch that is vital for cellular fitness. Remarkably, the traditional terminology of "mitochondrial function" has changed from apoptosis and bioenergetics to other key biological processes such as immunity/inflammation, intracellular and endocrine signalling, and complex metabolic processes. 31 
| G ENOTOXI C S TRE SS THEORY OF AG EIN G
Genomic instability seems to be a major stochastic mechanism of ageing. [32] [33] [34] This hypothesis is supported by much experimental evidence, among which, the human progeroid syndromes and transgenic animal models are the most convincing. DNA lesions appear during ageing in both the nuclear and the mitochondrial DNA.
Several studies have indicated that free radicals and oxidative stress probably are the most important source of ageing-related DNA mutations. The major signalling pathways induced by genotoxic stress are p53, NF-kB and PARP-1. [35] [36] [37] Recently, it was demonstrated that the activation of NF-kB signalling is one of the cellular hallmarks evoked by DNA damage. 38, 39 Surveys such as that conducted by
Metformin has an indirect effect on survival, proliferation, apoptosis, and inflammation via modulating NF-kB pathway efficiency
Rodier et al 40 showed that the persistent DNA damage in senescent cells can trigger the secretion of inflammatory cytokines, such as 
| EFFEC TS OF ME TFORMIN ON AG EING
Human ageing and ageing-related diseases are becoming one of the greatest challenges. [1] [2] [3] Evidence from in vitro studies and animal models also suggests that metformin may influence metabolic and cellular processes associated with the development of chronic conditions of older age. 42 is critical for ageing and ageing-related disorders such as cancer and T2DM. In our previously published data, we suggest that the in vitro short-term effect of metformin in the pharmacologic concentration has a protective effect against pro-oxidant stimulus-induced DNA damage in lymphocytes of elderly subjects. 17, 49 Although the mechanism of metformin is still unclear at the molecular level, fortunately, a wealth of recent studies have determined that metformin provides a glucose-lowering effect inhibiting hepatic gluconeogenesis, via activating 5′ AMP-activated protein kinase (AMPK)-one of the prominent metabolic sensors of the cell. 50 AMPK also mediates the downregulation of the fatty acid synthesis pathway, the mechanistic target of rapamycin (mTOR) and acetyl- According to bioinformatic analysis from several aged tissues, NF-kB was indicated to be the most associated transcription factor altered in gene expression during the ageing, 60 and reducing NF-kB activity is reported to attenuate the accelerated ageing of a mouse model of progeria. 61 NF-kB activation leads to the NF-kB-dependent transcription of genes coding for survival signals, inflammatory cytokines, cell-cycle modulators, and angiogenic and growth factors, all are key drivers in a tumour-promoting environment.
We have indicated previously that metformin has a protective effect on an in vitro model of ageing 3T3 fibroblasts under high glucose conditions in case of cell proliferation, collagen I and III production, escaping apoptosis and reducing NF-kB (p65) activity. 62 Metformin was recently found to have a protective effect against skin ageing.
Protein glycation contributes to skin ageing as it deteriorates the existing collagens by cross-linking. The progressive increase in AGE during ageing not only causes oxidative damage to cellular macromolecules but also modulates the activation of NF-kB. NF-kB also regulates skin ageing by regulating the expression level of collagenase, namely MMP-1, in dermal fibroblasts, 63, 64 which then exerts degradation of the dermal type I collagen. 66 Moreover, several reports have revealed that inhibition of NF-kB activation suppresses MMP-1 expression in several cells including dermal fibroblasts. 65, 66 Metformin may restore collagen production by decreasing the NFkB activity. Meanwhile, collagen production and cell proliferation may be regulated by NF-kB activity ( Figure 3 ). For example, the experimental data presented in our previous publication confirm that high glucose condition accelerates ageing-related alterations of the collagen production and NF-kB (p65) DNA-binding activity while metformin may ameliorate these effects as an anti-diabetic agent and supports the interest of these biomarkers of ageing. In addition,
we claimed that metformin not only significantly decreased RELA/ p65 expression but also had a possible direct anti-ageing effect on a primary culture of dermal fibroblasts from the aged human skin at different glucose concentrations which could be partially mediated via promotions of COL1A1 and COL3A1 expression. 67 Taken together, these findings can provide a possible mechanism for the anti-ageing and potential inhibitory effects of metformin on NF-kB, observed in vitro models of human cells in severe hyperglycaemic conditions.
| EFFEC TS OF ME TFORMIN ON AG EING -REL ATED D IS E A S E S
Ageing in humans is a well-known primary risk factor for many diseases and conditions, among them are diabetes, cardiovascular diseases, neurodegenerative diseases, and cancer. Indeed, the risk of death due to these conditions is dramatically elevated in older ages.
For this reason, there is a need for the development of new attempts to improve and maintain health in the older subject. 68 Therefore, researchers have identified effective mechanisms involved in ageing, the prevention of ageing and the delay of ageing-related diseases.
Thus, the possibility of a commonly used versatile drug, metformin, has been examined to reverse relevant aspects of the process of ageing and ageing-related diseases. Metformin has been shown to have pleiotropic effects on ageing-related conditions, making metformin a potential candidate for the treatment of ageing-associated disorders like T2DM, cancer, obesity, neurodegenerative and cardiovascular diseases. 69 
| T YPE II D IAB E TE S AND ME TFORMIN
Type 2 diabetes mellitus is defined by insulin resistance and is often accompanied by numerous sequela or co-morbidities including dyslipidemia, hypertension, atherosclerosis, and obesity. 70 NF-kB has been implicated in insulin resistance and glucose metabolism by both pharmacologic and genetic suppression approaches. 71 Upregulation of NF-kB signalling in hepatocytes results in a T2DM phenotype. 72 It is further hypothesized that innate immune activation and inflammatory response underlie T2DM and its associated features. 73 Thus, aberrant NF-kB activation in numerous tissues including adipose, pancreas, and liver contributes to disease pathology observed in patients with T2DM.
Clinical trials state that the anti-hyperglycaemic action of metformin is multifactorial and has been attributed to a diminished intestinal absorption of carbohydrates, reduced gluconeogenesis and oxidative stress, and increased glucose uptake. One of the major
The aging process of 3T3 fibroblasts is a combination of decreased cell proliferation and collagen production and increased apoptosis under high glucose concentrations. Metformin can block aging via inhibiting NF-kB activity mechanisms postulated to explain the hyperglycaemic action of biguanides is the enhancement of peripheral glucose uptake. 73, 74 This improvement in peripheral glucose disposal has been explained by an increase in insulin binding to membrane receptors, 75 and by activation of post-receptor events. 73, 76 Recently, we suggested that metformin increased the insulin receptor numbers in liver tissue in alloxan and streptozotocin-induced diabetic rats. 15 Furthermore, impaired glucose tolerance (IGT) sites are associated with increased and varying risk of developing T2DM. IGT has been associated with an increased risk of cardiovascular events and increased mortality. 77 We have concluded that metformin increases glucose transport in non-insulin target tissue like erythrocytes and platelets in IGT and T2DM. 78 A disorder in lipid metabolism is a common finding in diabetes.
An effect of metformin on lipid metabolism has also been advocated that biguanides have a beneficial effect on lipid metabolism. It is also known that biguanides may reduce the oxidation of free fatty acids. 77, 78 Previous in vitro and in vivo studies have demonstrated that metformin improves antioxidant activities in various tissues and acts to limit lipid peroxidation. 15, 49 The putative mechanism of lipid peroxidation in metformin action is still unknown in ageing-related diseases.
| C ARD I OVA SCUL AR D IS E A S E AND ME TFORMIN
Many clinical studies have reported that metformin has cardiovascular protective effects and reduces the incidence and mortality of cardiovascular events via the mechanisms which are still unclear.
Metformin treatment is reported to reduce effectively the risk of myocardial infarction and death compared to sulphonylurea and insulin treatment. [79] [80] [81] Similarly, in their cohort study of metformin Metformin treatment of rat aortas is reported to reverse the hyperoxia-induced abolishment of the vascular relaxation in response to acetylcholine. 84 Moreover, metformin can reduce inflammatory response, as well as improving the endothelial cell function. 85, 86 Accumulating evidence suggests that inflammatory processes participate in T2DM and its atherothrombotic manifestations. In atherosclerosis as an inflammatory disorder, NF-kB plays a central role in mediating cytokines, growth factors, receptor signalling proteins, cell adhesion molecules, and other proteins of immunity in cell types resident to the plaque microenvironment, ie, endothelial cells, SMCs, and macrophages. 87, 88 Activation of NF-kB transcriptionally activates multiple pro-inflammatory genes, including those that encode the pro-atherogenic cytokines IL-6 and IL-8. As noted by Isoda et al, 85 metformin can exert a direct vascular anti-inflammatory effect by inhibiting NF-kB through blockade of the PI3K-Akt pathway.
| C AN CER AND ME TFORMIN
Metformin is used as an anti-diabetic medication in T2DM throughout the world and has started to become a common anticancer agent. 89 One of the emerging questions in cancer biology is: "How is inflammation and metformin usage linked to cancer?" In a cohort study with T2DM patients, in new metformin users, a significant decline in cancer prevalence is found among metformin users (7.3%) compared to the controls (11.6%). 90 Metformin significantly reduces the proliferation of cancer cell and tumorigenesis although its mechanism has not been well understood.
Epidemiological studies indicate that women with T2DM are more likely to develop breast cancer. Along similar lines, a metaanalysis study argues that T2DM is related to a higher risk of breast cancer by 23%, particularly in postmenopausal women. 95 In an observational study including women with T2DM, the type 2 diabetics' who used metformin in the long-term have been found to have lower risk of cancers, especially breast cancer. 96 On the basis of the currently available epidemiologic evidence, it seems fair to suggest that the reduced risk of cancer in patients with diabetes through metformin uptake becomes widespread in the field of oncology.
Recent studies have exhibited that metformin, both directly and indirectly, shows its anti-proliferative effects on the breast cancer cells by developing insulin sensitivity, and therefore reducing hyperinsulinaemia. 97, 98 Mainly, these effects of metformin have been shown due to AMPK. Metformin also inhibits the cellular energy cascade via repressing the AMPK-independent pathway by activating the hexokinase-II enzyme in the glycolysis pathway and disrupting glucose uptake. 99 Tumour invasion and metastasis are generally in charge of many complex biological processes in cancer. Cell-extracellular matrix (ECM) connections, degradation of intercellular adhesion molecules and ECM invasion via lymph and blood vessels are crucial processes for the cancer invasion and metastasis. 100 Several proteolytic enzymes act a part and play a critical role in the degradation of the microenvironment in cancer, including the ECM and basal membrane. 101 Underlining the role of MMPs in tumour invasion and metastasis is crucial as they block tumour cells' spread. 102 MMPs are a family of structural and functional zinc-dependent endopeptidases and participate in the proteolysis of several ECM components, such as collagen, and fibronectin. 101 The activity of these proteins is accurately regulated to inhibit tissue degradation under physiological conditions. The balance of these conditions may be likely to be broken down in tumour cells which are able to invade other tissues. 103 Until now, most of the researchers have unveiled the expression profiles of MMP-2 and MMP-9, which are capable of degrading type IV collagen. 104 Degradation of the basal membrane, which separates the stromal tissue from epithelial cells, is an obligatory step required for tumour invasion, resulting in increased expression levels and activities of MMP-2 and -9. 105 As in transcription factors, there are many activator proteins such as AP-1 (activator protein-1) and NF-kB in the expression of MMP-2 and -9 in the transcription processes.
The balance between NF-kB activation and control is lost during pathological conditions such as chronic inflammation and cancer, but the overarching role played by the NFKB1 gene in carcinogenesis still remains incompletely understood.
In one of our previous studies, we pointed out that metformin acts as a potential agent against breast cancer in a dose-dependent manner according to the outcomes of our in vitro study. We observed that metformin inhibited NF-kB by its inhibition of nuclear translocation as well as decreased expression of proteins involved in the invasion pathway of breast cancer, such as MMP-2 and MMP-9
( Figure 4) . 106 These results support the observation that metformin may have a protective effect against breast cancer via modulating NF-kB.
| CON CLUS ION
NF-kB, one of the prominent inflammation marker transcription factors, can be modulated by metformin in anti-ageing process.
Therefore, this review highlights the relationship between the activity and expression of NF-kB in the presence of metformin and the risk of ageing and different ageing-related disorders. More research is required to better delineate the specific role of NF-kB activation in ageing, ageing-related diseases, and cancer, which may also take us one step closer to the development of powerful anti-ageing, anticancer, and anti-inflammatory therapies in the future.
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F I G U R E 4 Metformin inhibits MMP-2 and MMP-9, thereby the invasion and metastasis of the breast cancer via NF-kB inhibition
